PackGene Receives Global Gene Therapy CRDMO Technology Innovation Leadership Award

PackGene Biotech has received the Global Gene Therapy CRDMO Technology Innovation Leadership Award from Frost & Sullivan, recognizing the company’s innovation, platform development, global service capabilities, and industrialization practices in the gene therapy CRDMO field.

The award was announced as part of the 2026 Frost & Sullivan Growth, Innovation and Leadership Best Practices Awards, also known as the GIL Awards. With a history spanning nearly 30 years, the GIL Awards recognize companies that demonstrate strong performance in technology innovation, commercialization, and industry advancement through in-depth industry research, multidimensional assessment, and independent expert evaluation.

The recognition highlights PackGene’s technical innovation capabilities, scalable production strength, and global service value. It also marks another step in the company’s growing industry influence as a gene therapy-focused CRDMO.

Gene therapy development requires coordination across multiple critical steps, from vector design and developability assessment to process development, scale-up production, quality control, and regulatory support. To address challenges such as long development timelines, complex technical workflows, and high quality requirements, PackGene has continued to build an integrated technology and service platform supporting customers from proof of concept, or POC, through IND development.

PackGene’s service portfolio covers key gene therapy modalities, including plasmid DNA, AAV, lentiviral vectors, and mRNA-LNP. The company provides research-grade and clinical-grade plasmid and AAV production services to support drug discovery, preclinical studies, IND submissions, and clinical development.

The company has built five core technology systems to support gene therapy development and industrialization. Its π-Alpha™ 2.0 AAV high-yield platform combines a proprietary suspension cell line, dedicated culture medium, high-yield dual-plasmid system, and systematic production process to support stable AAV scale-up and large-scale production.

PackGene’s π-Icosa AAV capsid screening platform is designed to identify candidate capsids with improved safety profiles and tissue- or disease-relevant targeting properties. The platform supports customers in improving project feasibility and commercial translation potential.

In addition to production platforms, PackGene provides key upstream development services, including vector design and developability assessment. The company’s platform has been refined through experience supporting more than 50 AAV clinical programs, building capabilities in process development, analytical testing, project management, and regulatory submission support.

With manufacturing sites and service teams in both China and the United States, PackGene has supported more than 2,000 pharmaceutical companies and research institutions across over 30 countries and regions.

PackGene said it will continue strengthening its core technology platforms, production capacity, and quality systems across plasmid DNA, AAV, lentiviral vectors, and mRNA-LNP. The company aims to further connect global innovation resources with industrialization capabilities to help accelerate gene therapy programs from POC to IND and from the laboratory to clinical development.